A microbicide gel currently in clinical trials may be effective in thwarting the transmission of both HIV and the HSV-2 genital herpes virus, according to Australian researchers at last week’s International AIDS Society conference in Sydney. VivaGel, currently being tested in human trials in Australia, Kenya and the U.S., was found to be 85 to 100 percent effective in deactivating the viruses during tests on lab animals.